Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15 ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

Werewolf Therapeutics provided a business update ... of WTX-124 in the fourth quarter of 2025. In addition, our PREDATOR platform continues to demonstrate its effectiveness as we presented ...

“Werewolf made considerable progress in 2024 ... of WTX-124 in the fourth quarter of 2025. In addition, our PREDATOR® platform continues to demonstrate its effectiveness as we presented updated ...

At close: March 13 at 4:00:02 PM EDT Loading Chart for HOWL ...

The movie that offended Sigourney Weaver by existing was 2004's 'Alien vs Predator,' a movie she saw as a shameless cash-grab ...